Get the Stockscreener App
2.00
2.04%
0.04
After Hours:
1.95
-0.05
-2.50%
Mereo Biopharma Group Plc Adr stock is traded at $2.00, with a volume of 848.59K.
It is up +2.04% in the last 24 hours and up +8.11% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$1.96
Open:
$2.0457
24h Volume:
848.59K
Relative Volume:
0.55
Market Cap:
$318.00M
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-10.00
EPS:
-0.2
Net Cash Flow:
$-21.55M
1W Performance:
-0.50%
1M Performance:
+8.11%
6M Performance:
+2.56%
1Y Performance:
-53.92%
1-Day Range:
$1.95
$2.0457
1-Week Range:
$1.92
$2.1066
52-Week Range:
$1.47
$4.72
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
2.00 | 311.83M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Rating of "Buy" by Brokerages - MarketBeat
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Adage Capital Partners GP L.L.C. Has $3.83 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Frazier Life Sciences Management L.P. Increases Stock Holdings in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - FinancialContent
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Analysts Set Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Price Target at $7.20 - MarketBeat
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):